HBsAg-BCG combined vaccine for intracutaneous injection and preparation method thereof
View Patent ↗The present invention provides a combined vaccine that includes hepatitis B vaccine (HeVac) and Bacille Calmette-Guerin (BCG) for intracutaneous injection and the method of preparation of such vaccine. The combined vaccine changes the now used liquid agent of the HeVac into a cryoprotectant, thus improving the heat stability of the HBsAg. Because of the cryoprotectant in the combined vaccine, the heat stability of the HBsAg is improved, and the efficacy of the vaccine is only slightly decreased after 30 days at 37° C., and the decrease is lower than with the liquid agent of the HeVac. The present invention changes the newborn's inoculation from two injections into one to simultaneously obtain prophylaxis of hepatitis B and tuberculosis.
1. A HBsAg-BCG combined vaccine for intracutaneous injection, consisting of the following components (0.2 ml per vial):
HBsAg (Hepatitis B virus surface Antigen)
5 μg~20 μg
BCG (Bacille Calmette-Guérin)
80 μg~120 μg
Gelatin
0.8~1.0 mg
Saccharose
8~12 mg
KCl
0.8~1.2 mg
Sodium glutamate
0.8~1.2 mg
NaCl
0.8~0.9 mg
H 2 O for injection
q.s.
pH
6.0~7.5.
2. A method for the preparation of HBsAg-BCG combined vaccine according to claim 1 , including the following steps:
(1) providing a stock solution of BCG, wherein 1 mL stock solution of BCG is consisted of the following components:
BCG
800~1200
μg
Gelatin
8~12
mg
Saccharose
80~120
mg
KCl
8~12
mg
Sodium glutamate
8~12
mg
H 2 O for injection
q.s. to 1
ml
pH
6.0~7.5
(2) providing a stock solution of HBsAg, wherein 1 mL stock solution of HBsAg is consisted of the following components:
HBsAg
50~200
μg
NaCl
8~9
mg
H 2 O for injection
q.s. to 1
ml
pH
6.0~7.5
(3) mixing the stock solution of BCG obtained in step (1) with the stock solution of HBsAg obtained in step (2) in a proportion of 1:1 (v/v) to prepare a semi-finished product of the HBsAg-BCG combined vaccine,
(4) distributing the semi-finished product of the HBsAg-BCG combined vaccine obtained in step (3) into vials, 0.2 ml per vial,
(5) lyophilizing the vials obtained in step (4) to prepare a finished product of the HBsAg-BCG combined vaccine, i.e. a lyophilized formulation, wherein the vials are precooled in a drying oven at −40° for 3-4 hours, frozen at −40° for 7-8 hours, dried in vacuum for 8-10 hours at a gradually increasing temperature, and dried in vacuum for 7-8 hours at a constant temperature of 30-35° C., the overall time amounting to 25-30 hours.
3. The HBsAg-BCG combined vaccine according to claim 1 , which is in a lyophilized form.